Definium Therapeutics, Inc. $DFTX Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its stake in Definium Therapeutics, Inc. (NASDAQ:DFTX) by 77.9% in the third quarter, Holdings Channel.com reports. The firm owned 9,104 shares of the company’s stock after selling 32,151 shares during the quarter. CenterBook Partners LP’s holdings in Definium Therapeutics were worth $346,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC raised its stake in shares of Definium Therapeutics by 4.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,832 shares of the company’s stock valued at $374,000 after purchasing an additional 382 shares during the period. TFB Advisors LLC boosted its position in shares of Definium Therapeutics by 2.5% during the third quarter. TFB Advisors LLC now owns 22,064 shares of the company’s stock worth $840,000 after buying an additional 541 shares during the period. Chicago Partners Investment Group LLC grew its holdings in shares of Definium Therapeutics by 16.9% during the third quarter. Chicago Partners Investment Group LLC now owns 8,535 shares of the company’s stock worth $304,000 after buying an additional 1,236 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Definium Therapeutics during the third quarter worth about $261,000. Finally, Profund Advisors LLC grew its holdings in shares of Definium Therapeutics by 216.0% during the third quarter. Profund Advisors LLC now owns 42,885 shares of the company’s stock worth $1,632,000 after buying an additional 29,314 shares in the last quarter. Institutional investors own 27.91% of the company’s stock.

Insider Buying and Selling

In other Definium Therapeutics news, CFO Brandi Roberts sold 3,377 shares of the firm’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $123,496.89. Following the completion of the transaction, the chief financial officer directly owned 394,528 shares in the company, valued at $14,427,888.96. This trade represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $1,153,783.50. Following the transaction, the chief executive officer directly owned 2,213,090 shares in the company, valued at $80,932,701.30. This trade represents a 1.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 71,098 shares of company stock valued at $2,626,115. 2.40% of the stock is currently owned by company insiders.

Definium Therapeutics Price Performance

Shares of NASDAQ DFTX opened at $33.00 on Friday. The stock has a market capitalization of $4.43 billion, a price-to-earnings ratio of -10.61 and a beta of 2.23. The business has a 50-day moving average of $36.19 and a 200-day moving average of $30.31. The company has a debt-to-equity ratio of 0.04, a current ratio of 15.53 and a quick ratio of 6.95. Definium Therapeutics, Inc. has a fifty-two week low of $10.46 and a fifty-two week high of $49.70.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Monday, November 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.09. As a group, sell-side analysts predict that Definium Therapeutics, Inc. will post -2.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on DFTX. Piper Sandler reissued an “overweight” rating and issued a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Canaccord Genuity Group set a $78.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, September 15th. UBS Group reaffirmed a “buy” rating and set a $70.00 price target on shares of Definium Therapeutics in a research note on Tuesday, September 15th. Maxim Group set a $55.00 price objective on shares of Definium Therapeutics and gave the company a “buy” rating in a report on Friday, August 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.24.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.